3EO Health
The World’s First Point-Of-Life Molecular Company
The World’s First Point-Of-Life Molecular Company
3EO Health is a groundbreaking molecular diagnostic company founded in 2021. Positioned as “The World’s First Point-Of-Life Molecular Company,” it focuses on expanding access to molecular testing at the point of care. The company's innovative technology significantly reduces costs, streamlines physician workflow, and removes barriers in point-of-care testing. 3EO Health aims to empower physicians with improved options to enhance patient care and extend the health system beyond traditional boundaries, including into the home, work, and community. Their ultimate goal is to empower every individual to optimize their health.
This United States based company operates within the E-commerce and Health Care sectors. Recently, on June 6, 2023, it secured a Non-Equity Assistance investment from MedTech Innovator. This strategic funding is likely to further propel 3EO Health’s disruptive innovation and expansion in the molecular diagnostics market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
06 Jun 2023 |
No recent news or press coverage available for 3EO Health.
We care about your data, and we'd love to use cookies make your experience better.
